Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumoursSofie Van Binnebeek, Christophe M. Deroose, L. Mortelmans et al.|European Radiology|2015Cited by 98
Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization StrategiesNiloefar Ahmadi Bidakhvidi, Christophe M. Deroose, Kristof Baete et al.|Cancers|2021Cited by 48
Inflammation-Based Index and <sup>68</sup>Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOCElin Pauwels, Christophe M. Deroose, Sofie Van Binnebeek et al.|Journal of Nuclear Medicine|2019Cited by 44
Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapySofie Van Binnebeek, Christophe M. Deroose, Kristof Baete et al.|European Journal of Nuclear Medicine and Molecular Imaging|2014Cited by 30
[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patientsElin Pauwels, Christophe M. Deroose, Sofie Celen et al.|European Journal of Nuclear Medicine and Molecular Imaging|2022Cited by 23